



ASX Announcement

02 September 2025

Cambium Bio Signs US\$2.0M+ Licensing Deal for Fibrin Biologic in Dental Applications

Sydney, Australia; 02 September 2025: Cambium Bio Limited (ASX:CMB) ("Cambium Bio", "Cambium" or "Company"), a clinical-stage regenerative medicine company, is pleased to announce it has entered into a term sheet with Keke Medtech, Inc. ("Keke") granting exclusive worldwide rights to develop and commercialise the Company's proprietary human platelet lysate-derived fibrin biologic for dental and oral wound-healing applications.

Key Transaction Highlights

Financial Terms

- **Upfront payment:** US\$250,000 (staged payment plan with initial US\$25,000 already received)
- **Development milestones:** US\$1.75 million total
 - US\$250,000 upon first-in-human trial initiation (required within 24 months)
 - US\$1,500,000 upon first regulatory approval
- **Commercial terms:** Double-digit royalties on net sales (10% on first US\$10M annually; 13% thereafter)
- **Sublicense revenue:** 20% share of non-royalty sublicense revenues

Strategic Value

- **Platform validation:** Independent third-party recognition of the Company's human platelet lysate technology potential beyond ophthalmology
- **Non-dilutive funding:** Provides capital without shareholder dilution as the Company advances the Elate Ocular® Phase 3 program
- **Retained focus:** Allows Cambium to maintain primary focus on dry eye disease while monetising the platform in complementary indications
- **Supply relationship:** Cambium remains the exclusive supplier of the fibrin biologic, ensuring an ongoing revenue stream

Licensed Field and Territory

- The exclusive license covers the fibrin biologic for dental and oral wound-healing applications, including:
 - Post-extraction socket healing
 - Periodontal and gum tissue regeneration
 - Alveolar bone regeneration
 - Dental implant integration
- **Territory:** United States, Southeast Asia, the Middle East, and Taiwan

Development Obligations

Keke will be responsible for all development costs and activities, with contractual obligations including:

- First patient dosing in clinical trials within 24 months
- Full funding of pre-clinical, clinical, and regulatory programs
- Diligent pursuit of regulatory approvals across the licensed territory

Platform Technology Overview

The fibrin biologic is a regenerative component derived from Cambium Bio's proprietary human platelet lysate (HPL) platform technology. During the manufacturing process of the Company's fibrinogen-depleted HPL (marketed as Aurarix®), the fibrin fraction is separated, creating a distinct therapeutic product rich in growth factors and regenerative proteins. This scalable manufacturing process enables the Company to develop multiple therapeutic products from a single platform, maximizing value across indications, including ophthalmology, orthopaedics, wound healing, and now dentistry. This transaction represents the first out-licensing agreement for a component of the Company's HPL platform.

Management Commentary

Karolis Rosickas, Chief Executive Officer of Cambium Bio, commented:

"This agreement represents a significant milestone for Cambium Bio, providing both strategic validation of our human platelet lysate platform and important non-dilutive funding as we advance Elate Ocular® toward Phase 3 trials. Keke's commitment to invest in clinical development for dental applications demonstrates the broad therapeutic potential of our platform components."

Importantly, this transaction allows us to maintain our primary focus on dry eye disease while capturing value from platform derivatives in complementary markets. The upfront and milestone payments will strengthen our balance sheet, while the manufacturing supply arrangement and the royalty structure ensure we participate in the long-term commercial success of the program."

Next Steps

- Execution of definitive License and Supply Agreements within 90 days
- Receipt of remaining upfront payment instalments per the agreed schedule
- Continued advancement of Elate Ocular® Phase 3 program (first patient expected Q4 CY2025).

About Keke Medtech, Inc.

Keke Medtech is a Taiwan-based medical technology company focused on developing innovative solutions for dental and oral health applications. The company has established distribution and clinical development capabilities across Asia-Pacific markets.

- ENDS -

About Cambium Bio Limited

Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company focusing on the development of innovative biologics for ophthalmology and tissue repair applications. The Company's proprietary technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Cambium Bio's lead product candidate, Elate Ocular®, is being developed to address significant unmet medical needs in the treatment of dry eye disease. In addition, the Company's stem cell platform, Progenza™, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. Cambium Bio is committed to advancing its pipeline through clinical development and commercialization, with the goal of providing

transformative treatments to improve patient outcomes. For more information about the Company and its programs, please visit www.cambium.bio

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Cambium Bio Limited.

For further information, please contact:
Acclime Australia – Company Secretary
Email: info@cambium.bio

Cambium Bio Limited
Unit 2.06/31 Lexington Drive, Bella Vista, NSW 2153 Australia
ABN 13 127 035 358
Phone: 1300 995 098
www.cambium.bio